肺癌患者放疗前后血液TGF—β1变化与淋巴细胞亚群变化趋势相关性分析被引量：6

A correlation analysis of the changes in plasma level of transforming growth factor betal and lymphocyte subset percentages after radiotherapy for patients with lung cancer

原文传递

导出

摘要目的研究肺癌患者放疗后血浆TGF—β1变化与肺癌近期疗关系，分析其与外周血淋巴细胞亚群变化趋势相关性。方法前瞻性收集2014-2016年在我院39例肺癌患者疗前、疗中及疗后血液标本，采用酶联免疫吸附试验测定血浆中TGF—β1表达水平，同时检测对应时间点患者外周血中淋巴细胞亚群变化，动态监测二者变化趋势。放疗结束后1个月复查胸部CT等，评价肿瘤近期疗效，根据RECIST标准分为治疗有效和无效。结果放疗后血浆TGF—β1水平降低患者近期疗效较好（P〈0．05）。放疗开始后2、4周及放疗结束时血浆TGF—β1和疗前相比变化水平与相同时间点的CD4（＋）T淋巴细胞（r=-0．581、-0．516、-0．648，P〈0．001）、CD8（＋）T淋巴细胞（r=0．558、0．545、0．626，P〈0．001），以及CD4（＋）／CD8（＋）值（r=-0．615、-0．648、-0．598，P〈0．001）变化水平显著相关。结论肺癌患者放疗后TGF—β1水平下降者近期疗效较好，其具体机制可能与机体抗肿瘤免疫有关。 Objective To investigate the relationship between the change in plasma level of transforming growth factor-beta1 （TGF-β1） after radiotherapy （RT） and short-term treatment outcomes in patients with lung cancer, and to analyze its relationship with the changes in lymphocyte subset percentages in peripheral blood. Methods In a prospective study, blood samples before, during, and after treatment were collected from 39 patients with lung cancer who were treated in our hospital from 2014 to 2016. Plasma level of TGF-β1 was measured by enzyme-linked immunosorbent assay. The percentages of lymphocyte subsets in peripheral blood were determined at each time point. At one month after RT, chest computed tomography was performed to evaluate the short-term treatment outcomes. The response evaluation criteria in solid tumors were used to determine whether there was any response or not. Results Patients with lower plasma levels of TGF-β1 after RT had significantly better short-term treatment outcomes （P〈0. 05）. The changes in plasma level of TGF-β1 after 2 and 4 weeks of RT and at the end of RT were correlated to the changes in the percentages of CD4（＋） T and CD8（＋） T cells and the CD4（＋）/CD8（＋） ratio at the same time point （ r = -0. 581, -0. 516, -0. 648, P〈 0. 001 ; r = 0. 558, 0. 545, 0. 626, P〈 0. 001 ; r = -0. 615, - 0. 648,-0. 598, P〈0. 001 ）. Conclusions Lung cancer patients with reduced TGF-β1 levels after RT have better treatment outcomes than those without decreases in TGF-β1 levels after RT. The mechanism may be related to anti-tumor immunity.